Dextenza With ILUX for Treatment of MGD

• Status: Enrolling by invitation
• Trial end date: 2021-05-30
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing iLUX MGD Treatment System.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Warrenville Eyecare
• Treatments: Dexamethasone; Prednisone

Criteria

Inclusion Criteria:

• A patient's study eye must meet the following criteria to be eligible for inclusion in the study:

• 18 years of age or older

• Evaporative DED with MGD and clinically significant inflammation

• Willing and able to comply with clinic visits and study related procedures

• Willing and able to sign the informed consent form

Exclusion Criteria:

• A patient who meets any of the following criteria will be excluded from the study:

• Patients under the age of 18.

• Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)

• Active infectious systemic disease

• Active infectious ocular or extraocular disease

• Altered nasolacrimal flow of either acquired, induced, or congenital origin

• Hypersensitivity to dexamethasone

• Patient being treated with either topical, oral, or intravenous steroids

• Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator